STEP THERAPY POLICY

POLICY:  Hydroxy-methylglutaryl-coenzyme A Reductase Inhibitors (HMG) Step Therapy

APPROVAL DATE:  06/12/2019; selected revision 08/07/2019

DRUGS AFFECTED:

- Lipitor® (atorvastatin tablets – Pfizer, generic)
- Lescol® (fluvastatin capsules – Novartis, generic)
- Lescol® XL (fluvastatin extended-release tablets – Novartis, generic)
- Mevacor® (lovastatin tablets – generic)
- Altoprev® (lovastatin extended-release tablets – Shinogi)
- Pravachol® (pravastatin tablets – Bristol-Myers Squibb, generic)
- Crestor® (rosuvastatin tablets – AstraZeneca, generic)
- Zocor® (simvastatin tablets – Merck, generic)
- Caduet® (atorvastatin/amlodipine tablets – Pfizer, generic)
- Vytorin® (ezetimibe/simvastatin tablets – Merck, generic)
- Livalo® (pitavastatin tablets – Lily/Kowa)
- Flolipid® (simvastatin oral suspension – Salerno)
- Zypitamag® (pitavastatin magnesium tablets – Medicure)
- Ezallor™ (rosuvastatin capsules – Sun Pharmaceutical)

OVERVIEW

Available hydroxy-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (HMGs), excluding combination products, include lovastatin, simvastatin, atorvastatin, pravastatin, fluvastatin, fluvastatin extended-release, rosuvastatin, Altoprev, Ezallor, Livalo and Zypitamag. Simvastatin is available combined with Zetia® (ezetimibe tablets) a selective intestinal inhibitor of cholesterol and related phytosterol absorption, as Vytorin®, which is available generically. Atorvastatin is available as a combination with amlodipine, a dihydropyridine calcium channel blocker, as Caduet®, which is also available generically. Flolipid® (simvastatin oral suspension) is the only HMG oral suspension available and it has the same indications as simvastatin tablets.

GUIDELINES/SCIENTIFIC STATEMENTS

In November 2013, the American College of Cardiology (ACC) and the American Heart Association (AHA) published guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular (CV) risk in adults. The guideline emphasizes the appropriate intensity of statin therapy to reduce CV risk. No statin is preferred, but instead, statins with related doses are categorized as “high-intensity” (lowers low-density lipoprotein cholesterol [LDL-C] by approximately ≥ 50%), moderate-intensity (lowers LDL-C by approximately 30% to < 50%), and low-intensity (lowers LDL-C by < 30%). Only atorvastatin and rosuvastatin are categorized as acceptable “high-intensity” statin therapy. The guideline also identifies four major groups who should be treated with an appropriate statin-intensive therapy. These groups include: 1) Individuals with clinical atherosclerotic CV disease (ASCVD), which includes patients with a past acute coronary syndrome (ACS), or history of myocardial infarction (MI), stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack (TIA), or peripheral arterial disease presumed to be atherosclerotic origin; 2) Individuals with primary elevations of LDL-C ≥ 190 mg/dL; 3) Individuals 40 to 75 years of age with diabetes and LDL-C between 70 to 189 mg/dL (without CV disease); and 4) Individuals 40 to 75 years of age without clinical ASCVD or diabetes with LDL-C between 70 to
189 mg/dL and have an estimated 10-year ASCVD risk of 7.5% or higher. According to the guidelines, clinical trial evidence clearly shows that ASCVD events are reduced by using the maximum-tolerated statin intensity in groups shown to benefit. There is substantially less evidence for non-statin medications in reducing ASCVD risk. Table 1 categorizes the different statin regimens as high-, moderate-, and low-intensity. Refer to the guideline for the most appropriate intensity for the individual patient. An update was recently published.\(^5\)

### Table 1. High-, Moderate-, and Low-Intensity Statin Therapy.\(^{14*}\)

<table>
<thead>
<tr>
<th>High-Intensity Statin Therapy</th>
<th>Moderate-Intensity Statin Therapy</th>
<th>Low-Intensity Statin Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daily dose lowers LDL-C on average by approximately (\geq 50%).</td>
<td>Daily dose lowers LDL-C on average by approximately 30% to 50%.</td>
<td>Daily dose lowers LDL-C on average by &lt; 30%.</td>
</tr>
<tr>
<td>Atorvastatin (40 mg(^\dagger)) to 80 mg</td>
<td>Atorvastatin 10 mg (20 mg)</td>
<td>Simvastatin 10 mg</td>
</tr>
<tr>
<td>Rosuvastatin 20 mg (40 mg)</td>
<td>Rosuvastatin (5 mg) 10 mg</td>
<td>Pravastatin 10 mg to 20 mg</td>
</tr>
<tr>
<td>Simvastatin 20 mg to 40 mg(^\ddagger)</td>
<td>Pravastatin 40 mg (80 mg)</td>
<td>Lovastatin 20 mg</td>
</tr>
<tr>
<td>Lovastatin 40 mg</td>
<td>Lovastatin 40 mg</td>
<td>Fluvastatin 20 mg to 40 mg</td>
</tr>
<tr>
<td>Fluvastatin extended-release 80 mg</td>
<td>Fluvastatin 40 mg BID</td>
<td>Livalo 2 mg to 4 mg</td>
</tr>
<tr>
<td>Livalo 2 mg to 4 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\(^*\) Used in the randomized controlled trials reviewed by the expert panel. Of note, individual responses to statin therapy varied in the randomized controlled trials and should be expected to vary in clinical practice. There might be a biologic basis for a less-than-average response. LDL-C – Low-density lipoprotein cholesterol; \(^\dagger\) Evidence from one randomized controlled trial only and down titration is recommended if the patient is unable to tolerate atorvastatin 80 mg; \(^\ddagger\) Although simvastatin 80 mg was assessed in randomized controlled trials, initiation of simvastatin 80 mg or titration to 80 mg is not recommended by the Food and Drug Administration due to the increased risk of myopathy, including rhabdomyolysis; BID – Twice daily.

All of the HMGs have good capacity to lower elevated LDL-C. However, there is some variability among the products. Atorvastatin and rosuvastatin are considered “high-potency” HMGs because of their ability to reduce LDL-C by -60% and -63%, respectively, at maximal approved dosages. Ezetimibe plus simvastatin (Vytorin) also achieves comparable LDL-C reductions as atorvastatin and rosuvastatin with reductions of 60% at maximal dose. Table 2 cites the LDL-C reductions with HMGs, including ezetimibe plus simvastatin (Vytorin).\(^{1,7,9}\) Livalo, which is not included in the table due to different dosage range, lowered LDL-C by -31\%, -39\%, and -44\% at 1 mg, 2 mg and 4 mg once daily (QD) doses, respectively.\(^8\)

### Table 2. Estimated Percent LDL-C Reduction of the HMGs According to Prescribing Information in Patients with Primary Hypercholesterolemia.\(^{1,7,9}\)

<table>
<thead>
<tr>
<th>Drug</th>
<th>5 mg/day</th>
<th>10 mg/day</th>
<th>20 mg/day</th>
<th>40 mg/day</th>
<th>60 mg/day</th>
<th>80 mg/day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lovastatin</td>
<td>N/A</td>
<td>21%</td>
<td>27%</td>
<td>31%</td>
<td>N/A</td>
<td>42%*</td>
</tr>
<tr>
<td>Pravastatin</td>
<td>N/A</td>
<td>22%</td>
<td>32%</td>
<td>34%</td>
<td>N/A</td>
<td>37%</td>
</tr>
<tr>
<td>Simvastatin</td>
<td>26%</td>
<td>30%</td>
<td>38%</td>
<td>41%</td>
<td>N/A</td>
<td>47%</td>
</tr>
<tr>
<td>Atorvastatin</td>
<td>N/A</td>
<td>39%</td>
<td>43%</td>
<td>50%</td>
<td>N/A</td>
<td>60%</td>
</tr>
<tr>
<td>Fluvastatin</td>
<td>N/A</td>
<td>N/A</td>
<td>22%</td>
<td>25%</td>
<td>N/A</td>
<td>36%*</td>
</tr>
<tr>
<td>Fluvastatin extended-release</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>35%</td>
</tr>
<tr>
<td>Altoprev</td>
<td>N/A</td>
<td>24%</td>
<td>30%</td>
<td>36%</td>
<td>41%</td>
<td>N/A</td>
</tr>
<tr>
<td>Rosuvastatin</td>
<td>45%</td>
<td>52%</td>
<td>55%</td>
<td>63%</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Ezetimibe plus simvastatin (Vytorin)*</td>
<td>N/A</td>
<td>45%</td>
<td>52%</td>
<td>55%</td>
<td>N/A</td>
<td>60%</td>
</tr>
</tbody>
</table>

LDL-C – Low-density lipoprotein cholesterol; HMGs – Hydroxy-methylglutaryl-coenzyme A reductase inhibitors; N/A – Not applicable or available; \(^*\) Dosed as 40 mg twice daily; XL – Extended-Release; \(^*\) Value in the table is based on the simvastatin dose. Note: Values rounded to the nearest whole number.

**POLICY STATEMENT**

A step therapy program has been developed to encourage the use of one generic Step 1 HMG product prior to the approval of a Step 2 HMG product. If the step therapy rule is not met at the point of service, coverage will be determined by the step therapy criteria below. All approvals are provided for 12 months in duration.
Automation: For patients requesting a Step 2 HMG product, those with a history of one Step 1 HMG product within the 130-day look-back period are excluded from step therapy.

Step 1 HMGs: atorvastatin, lovastatin, pravastatin, simvastatin, fluvastatin, fluvastatin extended-release, rosuvastatin, atorvastatin/amiodipine and ezetimibe/simvastatin

Step 2 HMGs: Livalo, Flolipid, Lescol, Lescol XL, Altoprev, Pravachol, Zocor, Zypitamag, Lipitor, Crestor, Ezallor, Caduet, and Vytorin

CRITERIA

1. Authorization may be given for a Step 2 HMG if the patient has tried one Step 1 HMG.

2. Authorization may be given for Flolipid for patients who cannot or have difficulty swallowing tablets or capsules.

REFERENCES